Iovance builds gene therapy manufacturing facility in Philadelphia

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/ Jon Lovette)
(Image: Getty/ Jon Lovette)

Related tags: Gene therapy, Gene therapy candidate, Manufacturing, facility, Production line

Iovance amps up clinical and commercial immunotherapy production with a $75m (€67.3m), 136,000 square-foot build in Philadelphia’s Navy Yard.
PARK_Iovance
Architectural rendering of new facility (Image: DAGSAU)

The late-stage biotech will increase its production capacity for its tumor-infiltrating lymphocyte (TIL) technology-based therapeutics with the Philadelphia site. Iovance, headquartered in the San Francisco Bay Area, has research facilities in Florida and New York, but this will be its first manufacturing facility.

Iovance’s new facility will enable the company to produce its TIL products and its lead drug candidate lifileucel – which is in Phase II studies for the treatment of advanced melanoma – through scalable processes.

TIL therapyuses treats a patient with their own immune cells and involves the collection of a patient’s tissue sample that is then shipped to a manufacturing facility for processing. For Iovance, this supply chain requires the cells to be cryopressed after processing and shipped back to the patient for infusion.

A spokesperson for Iovance told us that the company chose to build in the city’s centrally-located  Navy Yard as it is close to the airport and has efficient access to transportation, which he said are key factors for a cell therapy where a rapid turnaround is imperative for accessibility.

Maria Fardis, president and CEO of Iovance said in a statement, “Building our own internal production capabilities will help us reduce the cost of operations which is necessary for offering broad access to TIL therapy.”

According to the company, the site will be designed to manufacture enough products for thousands of patients annually in both a clinical and commercial capacity.  

The facility is expected to be complete in 2021.

Related news

Related products

show more

The battle of performance in pharma production

The battle of performance in pharma production

Telstar Life Science Solutions | 26-Mar-2019 | Case Study

Telstar case study. Discover how a versatile freeze-dryer automatic loading & unloading systemDiscover how a versatile freeze-dryer automatic loading...

From Candidate to Clinic- European Capabilities

From Candidate to Clinic- European Capabilities

Catalent Pharma Solutions | 22-Oct-2018 | Technical / White Paper

Catalent’s Nottingham, UK facility focuses on early stage development of small molecule drug candidates from the bench to clinic. This facility offers...

Fill Release at the Right Time in the Right Place

Fill Release at the Right Time in the Right Place

Gelita AG | 19-Sep-2018 | Technical / White Paper

From rapid release in the stomach for e.g. analgesics to enteric release for fills with unpleasant aftertaste – GELITA delivers the respective gelatine...

Accelerate your supply chain as pressures intensify

Accelerate your supply chain as pressures intensify

William Reed | 17-Sep-2018 | Technical / White Paper

Food, Drink and Non-Food manufacturers are under pressure. Range reviews, massive retail mergers, the backlash against plastic packaging and the ongoing...

Related suppliers

Follow us

Products

View more